Rod McNeil

Independent Journalist and Consultant

Latest Contribution

Charts showing reduction in lesion growth rate with pegcetacoplan (syfovretm) vs sham pooled.

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

5 June 2023 |

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Diagram showing preliminary results from single-centre observational study evaluating intracameral Mydrane for phacoemulsification cataract surgery in high volume theatre lists. 

Improving cataract efficiency: insights and learnings from expert practitioners

1 December 2022 | | Ophthalmology, Cataract and Refractive

An evening surgical meeting sponsored by Théa Pharmaceuticals Ltd brought together leading experts to share insights and experience on practice strategies to enhance the efficiency of cataract surgery. Streamlining patient flow to optimise capacity and efficiency Qasim Mansoor, Consultant Ophthalmic...

Diagram showing new two-year data from TENAYA and LUCERNE demonstrate durable efficacy with faricimab using a treat-and-extend approach up to Q16W (4-monthly) dosing in patients with nAMD

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | Ophthalmology

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...